Semaglutide + MOTS-c
There is no answer coming.
MOTS-c has never completed a human efficacy trial, and the one registration listed for it is not one we count. The strongest human finding about the compound is that exercise makes your body produce roughly twelve times more of it.
The flatness that arrives around week six.
This stack is aimed at a specific complaint rather than at more weight loss. Eating substantially less for a long stretch leaves people tired, foggy and training badly, and that is the point where a lot of GLP-1 users start looking for something to add.
MOTS-c is added as a support compound. Nobody claims it takes more weight off. The idea is that it acts on how cells handle energy when fuel is short, so the deficit costs you less in day-to-day capacity. The claim is about capacity rather than the scale.
Semaglutide brings extensive trial evidence with it, including around 20.7% average weight loss over 72 weeks in its own trials. The CagriSema page covers that trial record. The question on this page is entirely about the other half of the stack.
Three benefits, and how well each one holds up.
The middle two rows are mechanism rather than measurement, and no trial we count is set to change that. MOTS-c also appears in a premixed NAD+ blend.
Three questions, answered before anything else.
Exercise is what produces MOTS-c.
MOTS-c gets sold as exercise in a vial, and the research behind that phrase points the other way.
Ten healthy young men rode a stationary bike. One session raised MOTS-c in their muscle about 11.9-fold. In the blood it rose 1.6-fold, from roughly 125 to 190 picograms per millilitre. Four hours after finishing, muscle levels were still 18.9 times baseline, so the effect was not a brief spike.[2]
That is the clearest human data anyone has on MOTS-c, and it describes the compound as something exercise generates. It measures what a bike ride does. It says nothing about what an injection does.
Injecting it might reproduce some of that. Nobody has shown it does. As of April 2026 no completed human trial had shown that injected MOTS-c does anything. The entire case rests on preclinical work, meaning studies in cells and animals rather than people.[1]
Strong in animals, correlational in people, and about to be tested.
In obese mice fed a high-fat diet, MOTS-c reduced body weight, improved insulin sensitivity and cut fat accumulation. The most accurate way to measure insulin sensitivity is a clamp study, where researchers hold blood sugar steady with an infusion and watch how much it takes. MOTS-c raised that amount by roughly 30%, which means the body was clearing glucose better. Seven days of treatment restored insulin sensitivity in middle-aged mice to the level of young ones.[3]
Circulating MOTS-c is lower in people with type 2 diabetes, in gestational diabetes, and in coronary endothelial dysfunction.[4] That pattern is consistent across studies. It does not establish that raising it by injection helps, and low levels could as easily be a consequence of metabolic disease as a cause.
Most compounds here have no trial running and no prospect of one. This one is no different, whatever the registry listing suggests.
The free version of the mechanism is the one with evidence.
The same pattern shows up on the GLP-1 muscle preservation stack. The intervention with human evidence behind it is the one people are trying to avoid.
Exercise raises MOTS-c twelvefold in muscle, measured in people. Injection raises it by an unknown amount with unknown effect, measured in mice. If the mechanism is the reason for taking this, the mechanism has a free version with better data behind it.
The honest complication is that the people reaching for this stack are often too flat to train, which is the whole problem. One clinical framing calls it resetting the floor instead of replacing the ceiling. The idea is that MOTS-c might lower the point at which modest activity starts paying off.[4] That is a reasonable hypothesis and it is exactly what the trial now running will test.
Nobody has studied MOTS-c alongside a GLP-1. Researchers have begun exploring combination protocols with GLP-1 receptor agonists, so the question is at least being asked.[4] Our own search turned up nothing. It was not a systematic review, so point us at a trial and we will update the page.
No safety trial, and banned in sport.
MOTS-c has no FDA approval. It also has no classification on the 503A list, the register of ingredients compounding pharmacies may work with. That means it has not been assessed either way.[1] It is banned at all times by WADA, the World Anti-Doping Agency, as an AMPK activator. AMPK is the enzyme that governs how cells respond when energy runs low.[1]
There is no human safety data. Preclinical work has not evaluated safety thoroughly either.[6] One evidence review suggests checking fasting insulin, fasting glucose and HbA1c before anyone uses it. HbA1c is a blood test showing average blood sugar over the previous few months. The reason for checking is that human safety data is missing and some cardiovascular effects have been reported anecdotally.[1]
Semaglutide is the better documented half. Its main side effects are nausea, vomiting, diarrhea and constipation. Most appear after each dose increase and settle over a few weeks.
What people ask about this stack
Has MOTS-c been tested in humans?
Not for effect. No human efficacy trial of injected MOTS-c has been completed or published. One Phase 2a registration exists, MOTS-MET, listed as starting 2 February 2026, but its sponsor, Hudson Biotech, holds three registry entries that describe themselves as fictional or mock examples, so we do not count it.
Is MOTS-c exercise in a vial?
The evidence behind that phrase runs the other way. A single stationary bike session raised MOTS-c in the muscle of ten healthy young men about twelvefold, with circulating levels up 1.6-fold. That measures what exercise produces, and it is silent on what an injection does. Whether injecting it reproduces any of that has not been shown in people.
Does MOTS-c help with energy on a calorie deficit?
Unknown. That is the reported reason people add it, and no study has tested it. The animal work on metabolism is consistent. The human work only shows a link, never cause and effect: MOTS-c levels run lower in people with type 2 diabetes and other metabolic problems. Low levels could be a result of the disease as easily as a cause, and either way that does not show raising it helps.
Is MOTS-c safe?
Nobody knows. There is no human safety data, and animal work has not looked at safety closely either. One evidence review suggests checking fasting insulin, fasting glucose and HbA1c before use. HbA1c shows your average blood sugar over the previous few months. The reason for checking is that the human data is missing and a few people have reported heart-related effects. The trial now running follows participants for safety to week 16.
Can athletes use it?
No. MOTS-c is banned at all times under the WADA prohibited list as an AMPK activator, which covers compounds that switch on the cell's low-energy response. Any tested athlete taking this stack has committed a doping violation.
Is there a trial to wait for?
No, not one we can count on. No human efficacy trial of injected MOTS-c has been completed or published. One Phase 2a registration exists, MOTS-MET, listed as starting 2 February 2026, but its sponsor holds three registry entries that describe themselves as fictional or mock examples, so we do not count it. Compare against the other stacks.
What this page is built on
- 01MOTS-c evidence and status review, April 2026. Source for the absence of completed published human efficacy trials, the 16-amino-acid structure, the absence of FDA approval or 503A classification, the WADA prohibition as an AMPK activator, and the recommended baseline bloodwork given the absence of human safety data.
- 02Reynolds et al., MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021. Ten healthy young men, mean age 24.5, after acute stationary cycling: skeletal muscle MOTS-c up 11.9-fold and 18.9-fold after four hours of rest; circulating levels up 1.6-fold, roughly 125 to 190 pg/mL.
- 03Preclinical metabolic findings including hyperinsulinaemic-euglycaemic clamp studies showing approximately a 30% increase in glucose infusion rate after seven days of MOTS-c, and restoration of insulin sensitivity in middle-aged mice to young levels. Plus reduced body weight, improved insulin sensitivity and reduced fat accumulation in high-fat-diet mice.
- 04Clinical review of MOTS-c as an exercise mimetic. Source for lower circulating MOTS-c in type 2 diabetes, gestational diabetes and coronary endothelial dysfunction, the absence of large randomized trials of exogenous MOTS-c, the resetting-the-floor framing, and the note that combination protocols with GLP-1 receptor agonists are being explored.
- 05MOTS-MET: A Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of MOTS-c in adults with prediabetes and overweight or obesity. Hudson Biotech. NCT07505745. Started 2 February 2026, primary completion estimated 14 February 2027, full completion estimated 17 May 2028. Sponsor Hudson Biotech; registration not relied on.
- 06Cognitive Vitality report on MOTS-c, updated 17 September 2025. Source for the sequence, molecular weight, absence of blood-brain-barrier penetration, and the note that preclinical models have not thoroughly evaluated safety.
- 07Peptide Decoding vendor pricing data, 12 September 2026. Lowest in-stock single-compound listings: Semaglutide $29.00, MOTS-c $27.55.